Patients are more aware of the treatment options available to them today than ever before. Healthcare providers are increasingly aware of the importance of the quality of the relationship with their patients and how that affects patient retention, new patient referral, and treatment outcomes. Patients demand the latest in technology when it comes to medical devices. Where Psoria-Light is concerned, not only can patients receive the latest NB-UVB or UVA LED technology available today, they can experience the benefit of seeing the progress of their therapy through successive treatment site images.
Third party awareness organizations, policy makers, and insurers are becoming increasingly aware of the cost of UV phototherapy (targeted or non-targeted) to the patient and the healthcare system as opposed to systemic/ biologic drug therapy. The short and long term impact on healthcare system costs associated with systemic/ biologic drug side effects can be substantial.
Side effects of systemic and biologic drugs your patients may endure include:
- Decreased kidney function
- Decreased liver function, failure, or death, symptoms including:
- Upset stomach or nausea
- Yellowing skin or eyes
- Hepatitis B infection in those who carry the virus in their blood
- Reduced immune system function including
- Lupus-like syndrome
- Chest pain
- Shortness of breath
- Joint pain
- Persistent rash
- Increased risk of cancer, such as lymphoma
- Nervous system problems including
- Serious infections including Tuberculosis and those caused by viruses, bacteria, or fungi
- New or worsening Psoriasis
- High cholesterol
- High blood pressure
- Skin sensitivity
- Dry or peeling skin
- Burning sensations
- Excessive hair growth
- Hair loss
- Multiple Sclerosis-like (MS-like) Syndrome
- Upper respiratory infections
Targeted UV phototherapy with Psoria-Light has a local, non-systemic effect, and is substantially less toxic than today’s systemic or biologic drug treatments. Systemic and/ or biologic drug treatments are still indicated for patients with severe, wide-spread cases- targeted UV phototherapy is not a replacement for drug therapy in these patients. Targeted UV phototherapy and certain drugs are used as concomitant therapy in a number of cases to treat psoriasis, eczema, and vitiligo with increasing treatment outcomes. Whether used in conjunction with other local or systemic drugs, targeted UV phototherapy can be used to accelerate therapeutic benefit and/ or reduce the strength of or amount of drug administered to patients, reducing overall toxicity and reducing effects such as tachyphylaxis.
Become a part of the massive movement towards less toxic, local treatment of these UV-treatable skin disorders. Psoria-Light is affordable and a variety of financing options are available to you.